One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis

Advanced AL amyloidosis has a very poor prognosis with a high risk of early mortality due to persistent organ dysfunction caused by insoluble amyloid fibril deposits. To improve patient outcomes, t...